Publications

Penack O, Henke E, Suh D, King CG, Smith OM, Na IK, Holland AM, Ghosh A, Lu SX, Jenq RR, Liu C, Murphy GF, Lu TT, May C, Scheinberg DA, Gao DC, Mittal V, Benezra R, van den Brink MRM. Depletion of vascular endothelial progenitor cells inhibits inflammation. Journal of the National Cancer Institute (in press).

Perales MA, Jenq R, Jenna JD, Wilton AS, Lee SSE, Castro-Malaspina HR, Hsu K, Papadopoulos EB, van den Brink MRM, Boulad F, Kernan NA, Small TN, Wolden S, Collins NH, Chiu M, Heller G, O'Reilly RJ, Kewalramani T, Young JW, Jakubowski AA. Second-line age-adjusted international prognostic index in patients with advanced Non-Hodgkin Lymphoma after T-cell depleted allogeneic hematopoietic stem cell transplant. Biology of Blood and Marrow Transplantation (in press).

Na IK, Lu SX, Yim N, Goldberg GL, Tsai J, RaoU, Smith OM, CG King, Suh D, Hirschhorn-Cymerman D, Palomba, ML, Penack O, Holland AM, Jenq RR, Ghosh A, Tran,H, Merghoub T, Liu C, Sempowski G, Ventevogel M, Beauchemin N, van den Brink MRM. The cytolytic molecules Fas ligand and TRAIL are required for thymic graft-versus-host-disease. Journal of Clinical Investigation 2010 120:1,343-56

Penack O, Smith OM, Cunningham-Bussel A, Liu X, Rao U, Yim N, Na IK, Holland AM, Ghosh A, Lu SX, Jenq RR, Liu C, Murphy GF, Brandl K, van den Brink MRM. NOD2 deficiency of host hematopoietic cells exacerbates Graft-versus-Host disease. Journal of Experimental Medicine 2009; 206:2101-10.

Rotolo JA, Stancevic B, Lu SX, Zhang J, Suh D, King CG, Kappel LW, Murphy GF, Liu C, Fuks Z, van den Brink MRM, Kolesnick R. Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease. Blood 2009 Aug 7 (Epub).

Goldberg GL, King CG, Suh DY, Smith OM, Ajodan R, Samstein R, Dudakov J, Chidgey AP, Boyd RL, van den Brink MRM. Lutenizing hormone releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation. Journal of Immunology 2009; 182:5846-54.

Jenq RR, King CG, Volk C, Suh D, Smith OM, Holland A, Lu SX, Zakrzewski JL, Goldberg GL, Diab A, Alpdogan SO, Penack O, Na IK, Kappel LW, Wolchok JD, Houghton AN, Perales MA, van den Brink MRM. Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses following murine allogeneic bone marrow transplantation. Blood. 2009; 113:1574-1580.

Kappel LW, Goldberg GL, King CG, Suh D, Smith OM, Ligh C, Holland A, Grubin J, Liu C, Iwakura Y, Mark N, van den Brink MRM. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 2009; 113:945-952.

Lu SX, Alpdogan O, Lin J, Balderas R, Campos-Gonzalez R, Wang X, Gao GJ, Suh D, King C, Chow M, Smith OM, Hubbard VM, Bautista JL, Cabrera-Perez J, Zakrzewski JL, Kochman AA, Chow A, Altan-Bonnet G, van den Brink MRM. STAT-3 and ERK1/2 phosphorylation are critical for T cell alloactivation and graft-versus-host disease. Blood 2008; 112:5254-5258.

Alpdogan SO, Lu SX, Patel N, McGoldrick S, Suh D, Budak-Alpdogan T, Smith OM, Grubin J, King C, Goldberg GL, Hubbard VM, Kochman AA, van den Brink MR. Rapidly proliferating CD44hi peripheral T cells undergo apoptosis and delay posttransplantation T-cell reconstitution after allogeneic bone marrow transplantation. Blood. 2008 112:4755-64

Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg GL, Jenq R. Holland AM, Grubin J, Cabrera-Perez J, Brentjens RJ, Lu SX, Rizzuto G, Sant'Angelo DB, Riviere I, Sadelain M, Heller G, Zuniga-Pflucker JC, Liu C, van den Brink MRM. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nature Biotechnology. 2008; 4:453-61.

Kim TD, Terwey TH, Zakrzewski JL, Suh D, Kochman AA, Chen ME, King CG, Borsotti C, Grubin J, Smith OM, Heller G, Liu C, Murphy GF, Alpdogan O, van den Brink MR. Organ-derived dendritic cells have differential effects on alloreactive T cells. Blood 2008; 111:2929-2940

Ramirez-Montagut T, Chow A, Kochman AA, Smith OM, Suh D, Sindhi H, Lu S, Borsotti C, Grubin J, Patel N, Terwey TH, Kim TD, Heller G, Alpdogan O, van den Brink MRM. IFNγ and FasL are required for graft-versus-tumor activity against renal cell carcinoma in the absence of graft-versus-host disease. Journal of Immunology 2007; 179:1669-1680.

Borsotti C, Franklin ARK, Lu SX, Kim TD, Smith OM, Suh D, King CG, Chow A, Liu C, Alpdogan O, van den Brink MRM. Absence of donor T cell-derived soluble TNF decreases graft-versus-host-disease without impairing graft-versus-tumor activity. Blood 2007; 110:783-786.

Goldberg GL, Alpdogan O, Sutherland JS, Muriglan SJ, Willis LM, Greenberg AS, Eng JM, van den Brink MRM*, Boyd RL*. Sex Steroid Ablation Enhances Immune Reconstitution Following Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Immunology 2007; 178:7473-7484.
*these authors contributed equally

Meada T, Merghoub T, Hobbs RM, Dong L, Meada M, Zakrzewski J, van den Brink MRM, Zelent A, Shigematsu H, Akashi K, Teruya-Feldstein J, Cattoretti G, Pandolfi PP. LRF regulates B versus T lymphoid lineage fate decision by opposing Notch signaling. Science 2007; 316:860-866.

Zakrzewski JL, Kochman AA, Lu SX, Terwey TH, Kim TD, Hubbard VM, Muriglan SJ, Suh D, Cabrera-Perez J, Radhakrishnan R, Heller G, Zuniga-Pflucker JC, Alpdogan O, van den Brink MRM. Adoptive transfer of in vitro generated T cell precursors enhances donor T cell reconstitution in allogeneic hematopoietic stem cell transplantation recipients. Nature Medicine 2006; 12:1039-1047.

Perales M-A, Diab A, Cohen AD, Huggins DW, Guevara-Patino JA, Hubbard VM, Engelhorn ME, Kochman AA, Eng JM, Mortazavi F, Alpdogan O, Terwey TH, Heller G, Wolchok JD, Houghton AN, van den Brink MRM. DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation. Journal of Immunology 2006; 177:4159-4167.

Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, Terwey TH, Hubbard VM, Kochman AA, Lu SX, Miles RC, Sakaguchi S, Houghton AN, van den Brink MRM. GITR Activation Breaks Self-Tolerance to Melanoma Differentiation Antigens and Enhances Anti-Tumor Immunity. Journal of Immunology 2006; 176:6434-6442.

Mayer-Kuckuk P, Doubrovin M, Bidaut L, Budak-Alpdogan T, Cai S, Hubbard V, Alpdogan O, van den Brink M, Bertino JR, Blasberg RG, Banerjee D, Gelovani J. Molecular imaging reveals skeletal engraftment sites of transplanted bone marrow cells. Cell Transplant 2006; 15:75-82.

Alpdogan O, Hubbard VM, Smith OM, Goldberg GL, Gray DH, Lu S, Kochman AA, Eng JM, Muriglan SJ, Boyd RL, van den Brink MRM. Keratinocyte growth factor (KGF) is required for post-natal thymic regeneration. Blood 2006; 107:2453-2460.

Kappel BJ, Pinilla-Ibarz J, Kochman AA, Eng JM, Hubbard VM, Leiner I, Pamer EG, Heller G, van den Brink MRM*, Scheinberg DA*. Depletion of Specific Immunity: Retention of Graft-Versus-Tumor Activity Without Graft-Versus-Host-Disease. Blood 2006; 107:2045-2051.
*these authors contributed equally

Waldman E, Hubbard VM, Kochman AA, Eng JM, Terwey TH, Muriglan SJ, Lu SX, Kim TD, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MRM. Absence of the β7 integrin results in less graft-versus-host disease due to decreased homing of alloreactive T cells to the intestine. Blood 2006; 107:1703-1711.

Terwey TH, Kim TD, Kochman AA, Hubbard VM, Lu SX, Zakrzewski JL, Ramirez-Montagut T, Eng JM, Muriglan SJ, Heller G, Murphy GF, Liu C, Budak-Alpdogan T, Alpdogan O, van den Brink MRM. CCR2 is required for CD8-induced graft-versus-host disease. Blood 2005; 106:3322-3330.

Hubbard VM, Eng JM, Ramirez-Montagut T, Tjoe KH, Muriglan SJ, Kochman AA, Terwey TH, Willis LM, Schiro R, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MRM. Absence of inducible costimulator on alloreactive T cells reduces graft-versus-host disease and induces Th2 deviation. Blood 2005; 106:3285-3292.

Alpdogan O, Muriglan SJ, Eng JM, Willis LM, Tjoe KH, Hubbard VM, van den Brink MRM. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 2005; 105: 865-873.

Muriglan SJ, Ramirez-Montagut T, Alpdogan O, van Huystee TW, Eng JM, Hubbard VM, Kochman AA, Tjoe KH, Riccardi C, Pandolfi PP, Sakaguchi S, Houghton AN, van den Brink MRM. GITR Activation Induces an Opposite Effect on Alloreactive CD4+ and CD8+ T Cells in Graft-versus-Host Disease. Journal of Experimental Medicine 2004; 200:149-157.

Friedman JS, Alpdogan O, van den Brink MR, Liu C, Hurwitz D, Boyd A, Kupper TS, Burakoff SJ. Increasing T-cell age reduces effector activity but preserves proliferative capacity in a murine allogeneic major histocompatibility complex-mismatched bone marrow transplant model. Biology of Bone Marrow Transplantation 2004; 10: 448-460.

Sugerman PB, Faber S, Willis LM, Murphy GF, Pappo J, Silberstein D, van den Brink MRM. Kinetics of gene expression in murine cutaneous graft-versus-host disease. American Journal of Pathology 2004; 164: 2189-2202.

Perez LE, Alpdogan O, Shieh J, Wong D, Merzouk A, Salara H, O'Reilly RJ, van den Brink MRM*, Moore MAS*. Increased plasma levels of stromal derived factor-1 (SDF/CXCL12) enhance human thrombopoiesis and mobilizes human colony forming cells in NOD/SCID mice. Experimental Hematology 2004; 32: 300-307.
*these authors contributed equally

Petrovic A, Alpdogan O, Willis LM, Eng JF, Greenberg AS, Kappel BJ, Liu C, Murphy G, Heller G, van den Brink MRM. LPAM (α4β7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal Graft-Versus-Host Disease. Blood 2004; 103: 1542-1547.

Alpdogan O, Muriglan SJ, Eng J, Willis LM, Greenberg AS, van den Brink MRM. Interleukin-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. Journal of Clinical Investigation 2003; 112: 1095-1107.

Alpdogan O, Schmaltz C, Muriglan SJ, Doubrovina E, Schiro R, Kappel BJ, Greenberg AS, Willis LM, Rotolo JA, O'Reilly RJ, van den Brink MRM. Insulin Growth Factor-I (IGF-I) enhances lymphoid and myeloid reconstitution after allogeneic bone marrow transplantation. Transplantation 2003; 75: 1977-1983.

Schmaltz C, Alpdogan O, Muriglan SJ, Kappel BJ, Rotolo JA, Ricchetti ET, Greenberg AS, Willis LM, Murphy GF, Crawford JM, van den Brink MRM. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 2003; 101:2440-2445.

Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J, Willis LM, Greenberg AS, Eng JM, Crawford JM, Murphy GF, Yagita H, Walczak H, Peschon J, van den Brink MRM. T cells require TRAIL for optimal graft-versus-tumor activity. Nature Medicine 2002; 8:1433-37.

Alpdogan O, Schmaltz C, Muriglan SJ, Kappel BJ, Perales MA, Rotolo JA, Halm JA, Rich BE, van den Brink MRM. Administration of Interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host-disease. Blood 2001; 98:2256-2265.

Schmaltz C, Alpdogan O, Horndasch KJ, Muriglan SJ, Kappel BJ, Teshima T, Ferrara JLM, Burakoff SJ, van den Brink MRM. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host-disease and graft-versus-leukemia. Blood 2001; 97:2886-2895.

Nature Reviews in Immunology
This is a pdf file. You will need Adobe Acrobat Reader to view the pdf.
Nature Reviews in Immunology
This is a pdf file. You will need Adobe Acrobat Reader to view the pdf.
Nature Medicine
This is a pdf file. You will need Adobe Acrobat Reader to view the pdf.

Site Map \| Index	Legal Disclaimer \| Privacy Practices \| Public Notices

©2010 Memorial Sloan-Kettering Cancer Center. 212-639-2000 1275 York Avenue New York, NY 10065.	PublicAffairs@mskcc.org